Updates are available Correction dated 2022-07-23
Click to view Correction: https://doi.org/10.1186/s13223-022-00705-y
-
Authors
Ansotegui, Ignacio J. http://orcid.org/0000-0002-6942-1511
Bernstein, Jonathan A.
Canonica, Giorgio W.
Gonzalez-Diaz, Sandra N.
Martin, Bryan L.
Morais-Almeida, Mario
Murrieta-Aguttes, Margarita
Sanchez Borges, Mario
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 14 December 2021
Accepted: 11 April 2022
First Online: 13 May 2022
Change Date: 23 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13223-022-00705-y
Declarations
:
: Not applicable.
: Not applicable.
: Ignacio J Ansotegui MD, PhD, declares personal fees from Abbott, Amgen, AstraZeneca, Bayer, Bial, Faes Frma, Hikma, Menarini, MSD, Mundipharma, Roxall, Sanofi, Stallergenes and UCB, outside the submitted work. Jonathan A. Bernstein, MD, declares personal fees from AstraZeneca, Sanofi, Regeneron, Novartis, Genentech, Shire/Takeda, CSL Behring, Pharming, Biocryst, Kalvista, Ionis, Merck, Blueprint Medicine, Biomarin, Intellia, Optinose, GSK and ALK, outside the submitted manuscript. Margarita Murrieta-Aguttes, MD, is a Sanofi employee. G. Walter Canonica, MD, Sandra Nora Gonzalez-Diaz, MD, PhD, Bryan L. Martin, MD, Mario Morais-Almeida, MD, PhD, and Mario A. Sanchez Borges, MD, had no conflict of interest to declare with the submitted work.
